Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001.
Fleming
T
T
Borer
J
J
Lipicky
R
R
Armstrong
P W
PW
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D026683:Advisory Committees; D000367:Age Factors; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D044383:Black People / Q000235:genetics; D002170:Canada; D002317:Cardiovascular Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017277:Drug Approval; D006333:Heart Failure / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D006801:Humans; D006947:Hyperkalemia / Q000209:etiology; D016032:Randomized Controlled Trials as Topic / Q000379:methods / Q000706:statistics & numerical data*; D044140:Receptor, Angiotensin, Type 1; D051437:Renal Insufficiency / Q000209:etiology; D013148:Spironolactone / Q000009:adverse effects / Q000627:therapeutic use; D015996:Survival Rate; D013777:Tetrazoles / Q000009:adverse effects* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration; D014633:Valine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068756:Valsartan; D001741:Black or African American
D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002317:Cardiovascular Agents; D044140:Receptor, Angiotensin, Type 1; D013777:Tetrazoles; D013148:Spironolactone; D000068756:Valsartan; D014633:Valine